Patients with HF who received SGLT2i therapy had significant improvement in functional capacity and QOL, regardless of sex, diabetes status, or ejection fraction, report researchers.
The majority of the US adult population meets criteria for subclinical CKM syndrome indicating "an urgent need for population-wide risk reduction measures."